Introduction {#s1}
============

Tobacco is identified as the leading preventable cause of premature death worldwide. It were estimated that 6 million people died from tobacco-related illness in 2014, of which 70% occur from low-income and middle-income countries.[@R1]

This study estimates economic costs of tobacco-related cancers in Sri Lanka and does not estimate the economic costs of other non-communicable diseases related to tobacco such as heart disease, cerebrovascular diseases and lung diseases or communicable diseases which contribute significantly to the burden of tobacco-related diseases.

According to the National Cancer Registry of Sri Lanka, one in every 10 Sri Lankans carries a lifetime risk of developing cancer. The incidence of cancer in Sri Lanka, standardised to the world standard population in the year 2009, was 86.4 and 89.1 per 100 000 populations in males and females, respectively.[@R3] Smoking and smokeless tobacco (ST)-related cancers of lip, oral cavity and pharynx, lung, oesophagus and colorectal cancer were the most common cancers among males. Among females, breast and cervix uteri cancers were the most common.[@R3] A large body of published epidemiological studies shows strong association between tobacco smoking, ST use and development of cancer. Cancers of the lung, lip, oral cavity and pharynx, oesophagus, larynx, stomach, kidney, pancreas, liver, bladder, colon and rectum are related to smoking,[@R4] while cancer of the lip, oral cavity, pharynx and oesophagus are related to ST use.[@R5] Studies on economic impact of smoking and ST-related cancers have not been previously carried out in Sri Lanka. Similar studies in other low-income and middle-income countries are too scarce. This study was conducted by National Authority on Tobacco and Alcohol, in collaboration with the Expert Committee on Tobacco, Alcohol and Illicit Drugs of the Sri Lanka Medical Association, WHO Country Office and the South East Asian Regional Office, with support from the Faculty of Pharmacy, Mahidol University and the Health Intervention and Technology Assessment Programme, Thailand. The findings of this study emphasises the necessity and the urgency for effective measures to address use of tobacco as a means of preventing cancer in Sri Lanka and the potential economic benefits of such initiatives.

Prevalence of tobacco smoking and ST use in Sri Lanka {#s1a}
-----------------------------------------------------

Tobacco is consumed in both smoked and non-smoked or smokeless forms. In Sri Lanka, the most widespread smoked form of tobacco is cigarettes, followed by bidi. Chewing and sniffing are the most common methods of using ST. WHO STEPwise approach to chronic disease risk factor surveillance (STEPS) of 2015 showed that 29.4% males and 0.1% females were current smokers in Sri Lanka, ST use was found in 26% of males and 5% of females.[@R7]

The WHO Global Youth Tobacco Survey 2015 shows that 3.2% of boys and 0.2% of girls between 13 and 15 years of age smoked at least once during the 30 days preceding the survey in Sri Lanka. The prevalence of ST use among students of this age group was 4.2% among boys and 0.5% among girls.[@R8] A study conducted among those over 30 years of age in the villages and estates of the Sabaragamuwa Province of Sri Lanka showed that 53.7% of the study population chewed betel daily; 27%of them were ever smokers.[@R9]

Methods {#s2}
=======

This study was conducted using the guideline 'Economics of tobacco toolkit: assessment of the economic costs of smoking' published by the WHO in 2011.[@R10] Accordingly, the prevalence-based approach was adopted for calculating the economic cost of tobacco use in Sri Lanka in 2015. The economic costs of tobacco-related cancers were calculated as direct costs for treating tobacco-related cancers and indirect cost due to productivity loss due to premature mortality and morbidity. The costs of smoking and smokeless tobacco were calculated separately and combined to estimate the total cost due to tobacco and ST-related cancers.

Types of cancer selected for the study {#s2a}
--------------------------------------

The costs of lung, lip, oral cavity and pharynx (3rd revision of the International Classification of Diseases for Oncology (ICDO-3): C00--C14 except C07-C08 salivary gland neoplasm) and oesophagus, larynx, stomach, kidney, pancreas, colorectal, liver and bladder cancer were calculated for smoking-associated cancers. Costs of cancer of the lip, oral cavity and pharynx (ICDO-3: C00--C14 except C07-C08) and oesophagus were calculated for ST.

Calculation of smoking/ST attributable fractions (AF) {#s2b}
-----------------------------------------------------

The following formula is used for calculating smoking/ST AF:

$$AF = \frac{\sum\limits_{j - 1}^{n}{P_{j}(RR_{j} - 1)}}{\sum\limits_{j = 1}^{n}{P_{j}(RR_{j} - 1) + 1}}$$

where j is the exposure category with baseline exposure or no exposure (j=0), RR(j) is the relative risk at exposure level j compared with no consumption and P(j) is the prevalence of the jth category of exposure.

AFs were calculated for each type of cancer. The AFs derived from the formula, together with the number of deaths and healthcare episodes, were used to estimate the number of healthcare episodes attributable to smoking in this study.

Calculation of direct cost {#s2c}
--------------------------

Direct healthcare cost included both government and out of pocket (OOPE) expenditures for outpatient and inpatient visits as well as clinic visits. Direct costs for outpatient care took into account frequency of clinic visits for the year and the cost to the government of providing such a service per person. An expert panel consisting of eight senior oncologists, two oncosurgeons, five public health consultants, a surgeon and three consultant physicians and two senior economists was consulted to estimate these costs. When calculating the inpatient care cost, the costs of surgery and pharmaceuticals, survival rates for certain cancers, the average intensive care unit (ICU) treatment days required for specific cancers, the average number of days in hospital were expert views of this panel. These costs reflected the experience of the clinicians in both the government and private sectors as all of them worked in both sectors.

Costs incurred by family members in accompanying the patient on different OPD visits and on entering hospital are included under OOPE by family.

Calculation of indirect cost {#s2d}
----------------------------

Loss of life or withdrawal from the workforce was calculated, considering the earnings for the period up to retirement based on average earnings adjusted for economic growth, the probabilities of survival and employment. The average earnings were taken from the Household Income and Expenditure Survey (HIES) data of the Department of Census and Statistics. Indirect costs in the form of lost earnings due to premature mortality was calculated using the 'scenario building method' based on mean income, incorporating annual growth, weights for probability of survival and employment with the lost earnings gap depending on age of death and assumed age of retirement.

A discount rate of 4.5% was used. Lost daily earnings due to absenteeism was calculated based on average monthly earnings as reported in the HIES.

Data sources {#s2e}
------------

Published reports of surveys conducted by government which are nationally representative such as the National Cancer Registry, reports from Registrar General's Department and Medical Statistics Unit of the Ministry of Health were used. Studies carried out by postgraduate students in the areas of community medicine and health economics were utilised in developing the best possible estimates when there was a paucity of data.

The extracted data were further validated through expert group meetings with the agreement of all experts. When the data were unavailable (eg, survival rates for certain cancers, the average number of ICU treatment days for specific cancers), the best estimates were made through the consensus of the experts.

Incidence of cancers among males and females were projected for 2015 based on data from the National Cancer Registry 2009 and cross-checked against Globocan 2012 IARC data base for Sri Lanka[@R3] which was used to estimate the number of patients with cancer in the year 2015.

The number of deaths from each type of cancer were obtained from the 2010 Indoor Mortality and Morbidity Report, of the Medical Statistics Unit, Ministry of Health, Sri Lanka.[@R12]

Income data were obtained from Household Income and Expenditure Survey year 2012--2013, of the Department of Census and Statistics, of Sri Lanka.[@R13]

The OOPE of indoor patients and outpatient department, clinic visits, hospital costs, ward management costs including hospital indoor cost per patient and human resource costs were obtained from a comprehensive study conducted in 2014.[@R14]

Length of stay in the hospital ward and number of clinic visits per year were obtained from the Statistical Cancer Review 2011 of the Medical Statistic Unit, National Cancer Institute, Sri Lanka.[@R15]

To calculate the AF for smoking, the prevalence of smoking and ST use were obtained from STEP survey in the year 2015 and RRs were derived from international literature, that is, systematic reviews on related cancers.[@R4]

Results {#s3}
=======

AFs for smoking and ST were calculated based on the RRs obtained through the published meta-analysis studies in the literature ([table 1](#T1){ref-type="table"}).

###### 

Relative risks (RR) and tobacco smoking and smokeless tobacco (ST) attributable fractions (AF) for different types of cancer

  ------------------------------------------------------------------------------------------------
  Types of cancer              RR          AF       Source of RR           
  ---------------------------- ----------- -------- -------------- ------- -----------------------
  Smoking                                                                  

  Lip, oral, cavity, pharynx   3.43        3.43     41.42%         0.10%   Gandini *et al* [@R4]

  Oesophagus                   2.52        2.28     30.67%         0.05%   Gandini *et al*[@R4]

  Stomach                      1.74        1.45     17.72%         0.02%   Gandini *et al* [@R4]

  Pancreas                     1.63        1.73     15.49%         0.03%   Gandini *et al* [@R4]

  Larynx                       6.98        6.98     63.51%         0.24%   Gandini *et al* [@R4]

  Trachea, lung, bronchus      9.87        7.58     72.08%         0.26%   Gandini *et al* [@R4]

  Cervix, uterine              --          1.73\*   --             0.03%   Zeng *et al* [@R17]

  Urinary bladder              2.8         2.73     34.37%         0.07%   Gandini *et al* [@R4]

  Kidney and renal pelvis      1.59        1.35     14.65%         0.01%   Gandini *et al* [@R4]

  Breast                       --          1.6\*    16.32%         0.03%   Chen *et al* [@R18]

  Liver                        1.53        1.7      13.36%         0.03%   Wanshni[@R19]

  Colon and rectum             1.09 and\            6.53%          0.01%   Wang *et al* [@R20]
                               1.24                                        

  ST                                                                       

  Lip, oral, cavity, pharynx   3.43        3.43     41.42%         0.10%   Thomas *et al* [@R5]

  Oesophagus                   2.52        2.28     30.67%         0.05%   Akhtar[@R6]
  ------------------------------------------------------------------------------------------------

\*Passive smoking RR.

Direct healthcare cost {#s3a}
----------------------

[Table 2](#T2){ref-type="table"} contains the direct healthcare costs of smoking and ST attributable cancers disaggregated by inpatient and outpatient care. Inpatient and outpatient care costs relate to state expenditure on healthcare while OOPE is borne by households.

###### 

Direct costs of tobacco smoking and smokeless tobacco (ST)-related cancers in US\$

  Type of cancer                  Inpatient cost   Outpatient cost   OOPE         Total healthcare cost
  ------------------------------- ---------------- ----------------- ------------ -----------------------
  Smoking                                                                         
  Lip, oral cavity, pharynx       5 875 994        297 726           3 920 452    10 094 172
  Oesophagus                      1 320 233        34 958            950 502      2 305 693
  Stomach                         333 534          6816              185 328      525 679
  Pancreas                        269 150          805               41 662       311 618
  Larynx                          2 337 541        158 792           1 483 735    3 980 068
  Trachea, lung, bronchus         6 900 016        73 037            2 881 932    9 854 985
  Cervix, uterine                 1796             118               1403         3318
  Urinary bladder                 675 634          41 389            490 614      1 207 638
  Kidney and renal pelvis         194 797          3818              80 391       279 006
  Breast                          49 993           11 445            72 475       133 913
  Liver                           216 774          993               70 108       287 876
  Colorectal                      293 352          16 637            180 203      490 193
  Total direct cost for smoking   18 468 817       646 536           10 358 806   29 474 159
  ST                                                                              
  Lip, oral, cavity, pharynx      593 885          30 091            396 239      1 020 216
  Oesophagus                      137 812          3649              99 217       240 678
  Total direct cost for ST        7 316 971        337 402           4 954 568    12 608 940

OOPE, out of pocket expenditure.

The total estimated direct healthcare cost is US\$29.5 million for smoking and US\$12.6 million for ST. Total direct cost accounts for 35% of the total economic cost attributable to tobacco ([table 4](#T4){ref-type="table"}).

Cancer of the lip, oral cavity and pharynx accounted for the highest direct healthcare cost of smoking while lung cancer was the second highest.

Indirect costs {#s3b}
--------------

As shown in [table 3](#T3){ref-type="table"}, the indirect cost of tobacco smoking was estimated to be approximately US\$54.3 million in 2015. Lung cancer accounted for the highest indirect cost. Premature mortality accounted for US\$33.2 million and absenteeism accounted for US\$21.2 million.

###### 

Indirect costs of tobacco smoking and smokeless tobacco (ST)-related cancers in US\$

  Type of cancer                    Absenteeism cost   Cost due to premature mortality   Total Indirect cost
  --------------------------------- ------------------ --------------------------------- ---------------------
  Smoking                                                                                
  Lip, oral, cavity, pharynx        7 637 854          9 837 834                         17 475 688
  Oesophagus                        1 830 603          4 111 458                         5 942 062
  Stomach                           305 345            1 340 760                         1 646 106
  Pancreas                          125 017            469 784                           594 802
  Larynx                            2 653 973          0                                 2 653 973
  Trachea, lung, bronchus           6 533 592          15 777 822                        22 311 414
  Cervix, uterine                   2671               950                               3621
  Urinary bladder                   1 315 914          983 093                           2 299 007
  Kidney and renal pelvis           155 718            0                                 155 718
  Breast                            110 946            12 397                            123 343
  Liver                             158 900            3 02 492                          461 392
  Colorectal                        336 092            332 995                           669 087
  Total indirect cost for smoking   21 166 628         33 169 587                        54 336 215
  ST                                                                                     
  Lip, oral, cavity, pharynx        7 861 888          9 602 394                         17 464 282
  Oesophagus                        3 012 494          4 203 925                         7 216 419
  Total indirect cost for ST        10 874 382         13 806 319                        24 680 701

The indirect costs of ST were estimated at approximately US\$24.7 million ([table 4](#T4){ref-type="table"}). Cancers of the lip, oral cavity and pharynx had higher indirect costs than for oesophageal cancer. A premature mortality cost was US\$13.8 million, while an absenteeism cost was US\$10.9 million for ST.

Indirect cost accounted for 65% of the total economic cost of tobacco-related cancers that were studied.

###### 

Summary of costing analysis in US\$ (millions)

  Cost categories                                        Cost of tobacco smoking   Cost of smokeless tobacco   Total cost
  ------------------------------------------------------ ------------------------- --------------------------- ------------
  Direct cost                                            29.5                      12.6                        42.1
  Inpatients care cost                                   18.5                      7.3                         
  Outpatient care cost                                   0.6                       0.3                         
  Out of pocket expenditure                              10.4                      5.0                         
  Indirect cost (cost of productivity loss)              54.3                      24.7                        79.1
  Cost of productivity loss due to Absenteeism           21.2                      10.9                        
  Cost of productivity loss due to premature mortality   33.2                      13.8                        
  Total                                                  83.8                      37.3                        121.2

Please note that rounding off has resulted in a slight discrepancy on the last row.

Discussion {#s4}
==========

Economic cost of tobacco-related cancer in Sri Lanka for the year 2015 was US\$121.2 million, which accounted for 16.06% of the US\$754.81 million allocated for recurrent expenditure for the state health sector for the year 2015.[@R21]

Economic cost of tobacco-related cancer was 0.15% of the total GDP (US\$82 838.66 million) in the year 2015 in Sri Lanka.[@R21]

Total tobacco tax revenue for the year 2015 was US\$592.7 million, which is 20.4% of our cost estimate for tobacco-related cancers.[@R21] However, economic costs of other conditions such as non-communicable diseases should be added to the cost to obtain a fair comparison between the taxes and economic costs.

Indirect costs made up the largest cost component accounting for approximately 65% of the total cost, which is similar to findings in previous studies undertaken on this topic.[@R22] The results show that tobacco exerts a substantial economic burden on the Sri Lankan population. It is imperative, therefore, that policymakers should consider these estimates in developing and implementing public policies and tobacco control measures.

In this paper, we present only the economic costs of selected tobacco-related cancers. It is well established that non-communicable diseases other than cancers comprises a substantial proportion of burden of tobacco-related diseases. The economic costs of these non-communicable diseases related to tobacco, which include heart disease, cerebrovascular disease, diseases of the respiratory and other systems are not included in the final costs presented. Therefore, these findings related to cancers, if taken alone, will substantially underestimate the total economic costs of tobacco in Sri Lanka. Studies have shown that the cost attributable to cancers ranged from 13% of the total cost of smoking in India[@R24] to 25% in Thailand[@R22] and 35% in Vietnam.[@R25] Given these findings, the total economic cost of tobacco in Sri Lanka for 2015 may fall within the range of US\$346.3 million to US\$932.3 million.

Although there are published costing studies in other countries, a direct comparison of the results is challenging as different studies include different types of diseases, costing methodologies, healthcare consumption patterns. Given similarities in consumption of tobacco products and the challenges posed by tobacco-related cancers in the South Asian region, this study methodology could also provide a sound framework for costing exercises in other countries in the region. The methodology used in this study could be further expanded in the future to consider impacts such as secondhand smoke and the opportunity cost of spending on tobacco in income constrained poor households.

There are some limitations of this study which should be taken into account when interpreting the results. First, this study involved reviewing data from different Departments and Ministries of the government of Sri Lanka. Therefore, the methodologies used, completeness and the timeliness of the reports differ. Second, when calculating the direct cost, cost of prevention, early detection and management of premalignant stages were not considered.

Third, while secondhand smoking is also related to many health hazards, we have only considered the passive smoking effects for breast and cervical cancers. The cost for providing healthcare in the private sector is not considered in this study. However, it is estimated that about 90% of the patients having malignancies seek treatment from the government sector.

When calculating the AFs, RRs were obtained from the systematic reviews, the local RR is available only for lung cancer. Lastly, psychosocial costs of suffering from cancer incurred by patients and their family members have not been assessed.

Conclusions {#s5}
===========

Burden of tobacco smoking and ST-related cancers in Sri Lanka is significant. As shown in this study, the economic costs associated with these diseases are enormous, resulting in negative impacts on both the healthcare system individual families and the country's economy. Therefore, policymakers should take note of this burden and take immediate and effective steps to control tobacco consumption.

###### What this paper adds?

-   The economic costs of cancers related to tobacco is significant in Sri Lanka. As seen in other studies carried out in different parts of the world, the indirect costs are greater than the direct costs.

-   Though tobacco use is linked to a large proportion on lung cancers epidemiologically, the largest proportion of the total economic costs of tobacco in Sri Lanka was due to cancers of the lip, oral cavity and pharynx.

-   The economic costs of cancers due to smokeless tobacco is a significant component of the total economic costs of tobacco-related cancers. This is a factor that needs consideration in tobacco control policy development in countries where smokeless tobacco use is prevalent.

-   The guidelines provided by the WHO to calculate the economic costs of tobacco can be adapted to estimate the economic costs of tobacco even in contexts where there are challenges in obtaining data and can be used in resource-poor settings to estimate these costs. This is important as the tobacco industry uses economic arguments in such countries to prevent implementation of effective tobacco control policies, such as policies that increase tobacco taxes.
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